News

In this role Mr Lowth will be responsible for finance and information services. Mr Lowth joins AstraZeneca from Scottish Power where he was finance director following two years

NGX-4010 is a dermal patch that has been studied successfully in three Phase III clinical trials in patients suffering from peripheral neuropathic pain conditions. Two Phase III clinical

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) proposal includes amending the summaries of product characteristics (SmPCs) for all approved ESAs to stipulate a

Fred Mermelstein, president and founder, said: “Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to

Trevor Hallam, executive vice president of R&D for Palatin, said: “We are pleased with the overall data from this exploratory trial. The efficacy response was consistent and robust

Zyflo CR and Zyflo (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of

Pafuramidine is among the first drugs to be considered for fast track status under new and more stringent State Food and Drug Administration (SFDA) rules recently introduced in

PS433540 is a dual-acting angiotensin and endothelin receptor antagonist (DARA) that is being developed as a potential treatment for hypertension and diabetic nephropathy. The study showed that all

Symphony GenIsis was formed in April 2006 by Symphony Capital Partners and capitalized with $75 million, to fund development of three of Isis’ drugs. As part of that